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ENGRAFTMENT OF INTERLEUKIN (IL)-2–ACTIVATED STEM CELLS IN
METASTATIC BREAST CANCER
Hugo F. Fernandez, Mark Goodman, Neil Spector, James Hanlon,
Rhonda Smith, Peter Cassileth
University of Miami, Miami, FL
Metastatic breast cancer is increasingly treated with high-dose
chemotherapy and stem cell rescue. In an attempt to decrease the
relapse rate by immunologic modulation, we began a trial using
IL-2–activated peripheral blood stem cells (PBSC). PBSC were
collected after chemotherapy and cytokine mobilization. Patients
received high-dose cyclophosphamide, thiotepa, and carboplatin
via continuous i.v. infusion over 4 days. One day before reinfusion
(day 1) the PBSC were incubated with IL-2 (6000 IU/mL in cul-
ture media)  24 hours. Cells were infused over 1 hour on day 0.
IL-2, 300,000 IU/m2 SC BID, was begun on day 0. G-CSF at 5
mcg/kg/day began on day 1 until WBC recovery. Data were com-
pared with that from a control group receiving the same
chemotherapy without IL-2 treatment. Medians are shown below.
IL-2 group Control group p
Number of patients 10 9
MNC infused/kg (108) 2.3 7.6 0.0001
CD34 infused/kg (106) 7 4 1.0 0.034
ANC recovery (days) 10 9 0.041
PLT recovery (days) 14 11 0.009
#RBC infusions required 4 2 0.006
# PLT infusions required 3 2 NS
Length of stay (days) 19 17 NS
All patients engrafted. There were no deaths due to therapy. The
lower CD34 cells infused may have slightly delayed blood count
recovery; however, the length of stay and number of platelet transfu-
sions did not differ. We conclude that IL-2–activated PBSC can be
given safely without impairing bone marrow recovery. Determining
the efﬁcacy of this approach is the aim of this continuing investigation.
TANDEM PERIPHERAL BLOOD PROGENITOR CELL (PBPC) TRANS-
PLANT IN CHILDREN WITH ADVANCED SOLID TUMORS
S.A. Grupp, M. Mogul, H.J. Weinstein, L. Diller
Children’s Hospital of Philadelphia, Philadelphia, PA; Emory University,
Atlanta, GA; Harvard Medical School, Boston, MA
Advances in the treatment of pediatric malignancies have made discour-
agingly little impact in the survival from metastatic neuroblastoma (NB)
and sarcomas. One approach has focused on increasing therapeutic inten-
sity while limiting toxicity. We have developed a program of intensive
induction chemotherapy followed by tandem myeloablative treatments
(high-dose treatments [HDT]) with PBPC rescue for treatment of
advanced stage NB (stage IV 1 year of age and stage III with MYCN
ampliﬁcation) and sarcomas (metastatic rhabdomyosarcoma [RMS] and
Ewings sarcoma [ES] as well as other soft tissue sarcomas). After study
entry, patients are treated with 2 courses of chemotherapy. One or 2 fur-
ther courses are used after to collect PBPC, and a total of ﬁve courses
plus local control complete the induction therapy. Patients then receive
courses of HDT, ﬁrst with cyclophosphamide, etoposide, and carbo-
platin, followed by melphalan plus TBI. Rapid hematopoietic recovery is
provided by PBPC, which in the second phase of the study have been
deleted of tumor cells by CD34 selection. Thirty-six patients, ages 13
months to 19 years, have completed or been taken off the protocol and 63
HDT cycles have been completed. Seventeen patients were diagnosed
with NB and 19 with sarcoma (8 RMS, 7 ES, 4 other). Engraftment has
been rapid, with a median time to ANC 500 of 11d and platelets
20,000 of 25d. Pheresis has been possible for each patient, and an aver-
age of 10106 CD34 cells/kg were collected for each cycle. There has
been no severe nonhematologic toxicity, including VOD. Four patients
who completed the ﬁrst HDT course were taken out of the study; 1 for
progressive disease between HDT1 and HDT2, 1 for elevated transami-
nases, and 2 at parental request. One patient had slow engraftment after
HDT2 following rapid engraftment after HDT1. With a median of 20
months of follow-up, 14 of 17 (82%) patients with NB and 9 of 19 (47%)
sarcoma patients remain in CCR.
WHAT IS THE OPTIMUM TIME FOR AUTOLOGOUS STEM CELL TRANS-
PLANTATION (ASCT) FOR PATIENTS WITH RECURRENT HODGKIN’S
DISEASE (RHD) WHO HAVE A LONG INITIAL REMISSION (INTERVAL
FROM 1 ST CR TO RELAPSE 1 YEAR)? 
H. Fung, A. Nademanee, A. Kashyap, A. Molina, J. Niland, 
M. O’Donnell, D. Snyder, P. Parker, A. Stein, R. Spielberger, 
A. Krishnan, R. Bhatia, S.J. Forman
City of Hope National Medical Center, Duarte, CA
For patients with RHD who have a long initial remission, it is unclear
whether ASCT should be performed at ﬁrst relapse or later relapse. To
address this question, we performed a retrospective analysis of 56
patients (1 rel  33, 1 rel  23) who had a long initial remission and
underwent ASCT at our center. The ratio of female to male patients was
22:34 with a median age of 33 (17–51). All patients received chemother-
apy before ASCT (median 3; 1–7); 30 (54%) had 2 regimens. Fifteen
patients (27%) had stage IV disease at diagnosis. The median duration of
ﬁrst CR was 27.3 months (12.3–97.5). Forty-eight patients (87%) had
chemosensitive rel, and 20 (27%) had extra-nodal disease at condition-
ing. Twenty-six patients (46%) received peripheral blood as the sole
stem cell source. The conditioning regimen was TBI-based (15) and
chemotherapy based (41). The median follow-up was 3.6 years (0.2–8.5).
Currently, 27 patients (48%) are alive and disease-free; 19 patients
(34%) had disease progression. Ten patients (18%) died of non-relapse
causes (NRM), including infections in two, VOD in three, and late PIP
in ﬁve. None of the patients (0/26) who received 2 prior regimens died
of NRM. Ten of 30 patients who received 3 regimens died of NRM.
The actuarial probability of rel, NRM, EFS, and OS was 43% (CI
29–59%), 19% (CI 9–38%), 46% (CI 32–61%), and 55% (CI 40–70%)
at 4 years, respectively. Univariate analysis showed a trend for longer
duration of initial remission (continuous) as a predictive factor for over-
all survival (p  0.08) but not DFS. We conclude that in this subgroup
of patients, delaying ASCT by repeated chemotherapy salvage attempts
increases the transplant-related morbidity and mortality, but fails to
improve survival. Therefore, earlier transplant is recommended.
CD34 SUBSET ANALYSIS OF PERIPHERAL BLOOD PROGENITOR CELL
FRACTIONS IN A RANDOMIZED TRIAL OF MOBILIZATION WITH FIL-
GRASTIM (G-CSF) VS. STEM CELL FACTOR PLUS FILGRASTIM
Lisa Hami, Karen Helm, Andrea Steele, Judith Stoltz, Melinda Bryant,
Stewart Turner,* Elizabeth Shpall
University of Colorado, Denver, CO; *Amgen, Thousand Oaks, CA
Thirty-eight patients at the University of Colorado were mobi-
lized with either ﬁlgrastim (G-CSF) or stem cell factor (SCF) plus
G-CSF in a prospective multicenter randomized trial. Patients
were evaluated for toxicity, stem cell collection, and engraftment
following high-dose chemotherapy with autologous stem cell sup-
port (Blood 12:1997) The peripheral blood progenitor cell (PBPC)
collections of 23 patients (GCSF  12, SCF  G-CSF  11) were
evaluated ﬂow cytometrically for the following subsets of CD34
progenitor cell populations: CD42a, CDw90, CD13, CD33,
CD38, and HLA-DR. A significantly greater number of
CD34/CDw90 cells were found in the collections of patients
mobilized with SCF  G-CSF (p  0.002). The CDw90 subset is
thought to represent a primitive subset of the progenitor cell popu-
lation. Engraftment rates were comparable in both treatment
groups. The clinical relevance of the CD34/CDw90 PBPC con-
tent produced by SCF  G-CSF may become evident in graft
manipulation studies where cells are purifed or cultured ex vivo.
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KINETICS AND SYMMETRY OF INITIAL CELL DIVISION OF HUMAN
CD34/CD38 CELLS FROM DIFFERENT ONTOGENIC AGE
S. Huang, K. Francis, P. Law, R. Ramakrishna, B.O. Palsson, A.D. Ho
University of California, San Diego, La Jolla, CA
To monitor the replication of hematopoietic progenitor cells
(HPC), we have developed a time-lapse camera system to directly
observe cell divisors. In this study, we combined the system with
index sorting and single-cell culture, and correlated the early replica-
tion behavior of CD34/CD38 cells to the ontogenic age of tissues,
such as fetal liver (FV), cord blood (CB), and adult marrow (AM).
Cell divisions were monitored every 12 hours for 8 days in medium
containing SCF, IL-3, IL-6, GM-CSF, and Epo. Replication of each
HPC was measured using membrane dye PKH-26. Symmetry of the
intital cell division and the division kinetics of progeny cells were cal-
culated from the singly sorted CD34/CD38 cells. 
Division/ Cloning Asymetric div./ Asymmetric div./
N total cell (%) efficiency (%) total cell (%) total div. (%)
FV 8 80.4 	 10.2 56.6 	 19.3 37.6 	 14.8 48.1 	 20
CB 4 76.3 	 3.8 30.9 	 7.4 34.7 	 14.7 45.6 	 17.5
AM 5 47.1 	 15.6 17.4 	 8.7 20.6 	 10.4 44.7 	 19.7
Our results also showed that 36–48 hours were required for
CD34/CD38 cells to complete the first mitosis, but only 12
hours for each subsequent division. The kinetic course was inde-
pendent of ontogenic age. We conclude that: (1) 40% of intital
cell divisions were deﬁnitely asymmetric—one of the daughter cells
became quiescent, while the other proliferated exponentially; (2)
the percent of cells undergoing asymmetric divisions decreases with
ontogenic age (FVCBAM); (3) the ratio of asymmetric to sym-
metric divisions is not correlated with ontogenic age. This unique
technology will permit precise deﬁnition of cytokine and cellular
determinants in the replication of primitive HPC.
LACK OF CORRELATION OF RESPONSE TO HIGH-DOSE PACLITAXEL
WITH HER-2/NEU OVEREXPRESSION IN STAGE IV BREAST CANCER
E. Jaffe, H. Hibshoosh, A. Troxel, L. Vahdat
Herbert Irving Comprehensive Cancer Center, New York, NY
Overexpression of Her-2/Neu in node-positive breast cancer
patients (patients) is considered to confer a worse prognosis includ-
ing decreased disease-free (DFS) and overall survival (OS). We
tested the hypothesis that Her-2/Neu overexpression correlates
with response to high-dose chemotherapy (HDC) with paclitaxel.
We studied 37 patients with responding stage IV breast cancer who
underwent sequential HDC. The ﬁrst intensiﬁcation was a 24-hour
infusion of paclitaxel at doses ranging from 400–825 mg/m2, the sec-
ond melphalan at 180 mg/m2, and the third a 96-hour infusion of
cyclophosphamide 6 g/m2, thiotepa 500 mg/m2, carboplatin 800
mg/m2. All cycles were given 3 weeks apart and supported with stem
cells and G-CSF. The pretreatment tumors were immunohistochem-
ically stained with mouse monoclonal antibody against c-neu and the
level of expression quantitated with a CAS200 image analyzer. Twen-
ty patients were Her-2/Neu positive () at 0.1 pg/cell and 17 were
negative (). The post-HDC responses were divided into 5 cate-
gories: complete response (11: 6/5), partial response (10: 6/4),
bone only with no change in bone scan after HDC (8: 3 /5), sta-
ble disease (2: 1/1), and stage IV with no evidence of disease (6:
4/2), which included patients with resected metastases pre-HDC.
The data was examined in several combinations, and no evidence of
correlation between Her-2/Neu overexpression and response to high-
dose paclitaxel was observed. Additionally, 9 patients have relapsed
since completing treatment, 5 of whom overexpressed Her-2/Neu.
There was no signiﬁcant difference in DFS between the two groups
in a logrank test and the correlation coefﬁcient between DFS and
Her-2/Neu overexpression was insigniﬁcant at 0.0107.
We conclude that overexpression of Her-2/Neu in stage IV
breast cancer does not correlate with treatment outcome with
high-dose paclitaxel.
EXPANDED CD3NK1.1 CELLS DEMONSTRATE AN IN VIV0 GRAFT-
VS.-LYMPHOMA EFFECT WITHOUT ACUTE GVHD
Maki Ito, Jeanette Baker, Judith A. Shizuru, Robert S. Negrin
Stanford University Medical Center, Stanford, CA
Although transplantation of highly puriﬁed allogeneic hematopoietic stem
cells (HSCs) may prove beneﬁcial in the reduction of graft-vs.-host disease
(GVHD), the potential loss of a graft-vs.-leukemia/lymphoma (GVL) effect
may offset this advantage. An idealized approach would be to transplant pure
HSCs plus selected populations of cells that confer GVL witbout GVHD. We
have carried out transplants of puriﬁed allogeneic HSCs in mice inoculated
with the B cell lymphoma, BCL1, and demonstrate that allogeneic HSC trans-
plants alone have no GVL effect. To augment GVL, in vitro expanded spleno-
cytes have been added that have potent in vitro anti-tumor cell activity. The
expanded cells are generated by long-term (3 weeks) culture of splenocytes in
the presence of IFN-
, IL-2, and adherent -CD3 monoclonal antibodies
(mAbs). The expanded cells are of one predominant phenotype (90%) as
determined by fluorescence-activated cell sorter (FACS) analysis, namely
CD3, NK1.1, CD8, and / T-cell receptor positive. The calculated fold
expansion of cells of this phenotype is 100. We have studied the tumor sup-
pressive activity of unprimed expanded CD3NK1.1 cells derived from
mouse spleen in an in vivo lymphoma relapse model. To establish a model of
tumor relapse, Balb/c (H-2d) mice were inoculated with 103 BCL1 tumor cells.
One week later they received lethal irradiation and 6000 puriﬁed HSCs of the
phenotype Thy-1loLin/loSca-1 with or without donor-matched expanded
CD3NK1.1 cells. Puriﬁed Thy-1loLin/lo Sca-1 HSCs effectively reconsti-
tute hematopoiesis in irradiated mice, but have no GVL activity. The donor
cells were from MHC mismatched C57BL/Ka (H-2b) mice. Relapse was mon-
itored by the appearance of splenomegaly and FACS analysis of peripheral
blood staining with a BCL1 speciﬁc mAb, 6A5. All mice were documented to
be hematopoietic cell chimeras by FACS analysis, and were without evidence
of acute GVHD. Control mice that received bone marrow plus 106 unfraction-
ated spleen cells all died of GVHD within 7 days. All control mice (n15)
transplanted with C57BL/Ka HSC only died of the tumor within 6 weeks fol-
lowing HSC transplant. In contrast, 80% of mice transplanted with 103 BCL1
cells plus C57BL/Ka HSC plus 107 expanded CD3NK1.1 cells are alive and
well 10 weeks posttransplant. We conclude that CD3NK1.1 cells are capa-
ble of augmenting GVL following allogeneic HSC transplants without causing
signiﬁcant GVHD.
PRELIMINARY RESULTS OF A PHASE I TRIAL OF AUGMENTATION OF
UNRELATED UMBILICAL CORD BLOOD (UCB) TRANSPLANTATION
WITH EX VIVO EXPANDED CELLS
J. Jaroscak, P. Martin, B. Waters-Pick, N. Chao, S. Castellino, 
C. Smith, J. Douville, S. Burhop, K. Goltry, A. Smith, J. Kurtzberg
University of North Carolina, Chapel Hill, NC
The best predictor of event-free survival after UCB transplantation
is cell dose. UCB units contain a restricted number of cells compared
with bone marrow. Aastrom Biosciences has developed a Clinical Cell
Production System (CPS) for the expansion of human hematopoeitic
stem cells (HSC). In this study, we evaluated the safety and efﬁcacy of
infusion of ex vivo expanded UCB cells in pediatric recipients. Five
patients, transplanted for malignant (n3) and non-malignant (n2)
conditions, were transplanted with 3107 unmanipulated UCB
cells/kg on day 0 and ex vivo expanded UCB cells 12 days later. On the
day of conventional transplantation, the CPS was inoculated with
1108 UCB cells. The cells were incubated and continuously per-
fused with medium containing PIXY 321, EPO, and FLT-3 ligand for
twelve days when the expanded cells were harvested, washed, and
infused without complications. All patients engrafted achieving an
absolute neutrophil count 500/L by 16–28 days posttransplant.
Results of expansion (Exp) are shown below:
Patient Cells 107/kg Fold exp. Fold CFU-GM exp.
1 5.6 4.3 158
2 2.1 2.6 37
3 2.9 4.0 225
4 0.3 1.5 60
5 4.8 8.4 95
These preliminary results demonstrate that banked UCB cells can be
thawed and expanded ex vivo in 12 days. Infusion of expanded cells is
well tolerated. Optimization of expansion conditions may increase cell
recovery and accelerate engraftment in recipients of UCB transplants.
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INTERIM ANALYSIS OF THE RISK OF SECONDARY LEUKEMIA AFTER
AUTOLOGOUS STEM CELL TRANSPLANTATION FOR BREAST CANCER
AND POTENTIAL USE OF HUMARA ANALYSIS
A.K. Joe, V. Rella, M. Grifﬁn, G. Nichols, L. Vahdat, C. Hesdorffer
Herbert Irving Comprehensive Cancer Center, College of Physicians and
Surgeons of Columbia University, New York, NY
Acute myelogenous leukemia (AML) and secondary myelodys-
plastic syndrome (sMDS) occur after treatment for malignancy.
Alkylating agents as well as the topoisomerase II inhibitors such as
the epipodophyllotoxins and doxorubicin are associated with either
sMDS or AML with a latency of 3–5 and 1–3 years, respectively. In
this interim analysis, we evaluated the incidence of AML and
sMDS in 238 breast cancer patients receiving high-dose chemo-
therapy (HDC) with autologous stem cell transplantation (ASCT).
One hundred ninety-six patients received one cycle of HDC con-
sisting of cyclophosphamide (6 g/m2), carboplatin (800 mg/m2) and
thiotepa (500 mg/m2; [CTCb]). Forty-two stage IV patients
received three tandem transplants with the last cycle consisting of
CTCb. All patients received chemotherapy before transplant. The
median cumulative doses of doxorubicin and cyclophosphamide
received before ASCT are 300 mg/m2 (range 0–640) and 3000
mg/m2 (range 0–15000), respectively. The median length of time
since the ﬁrst cycle of any chemotherapy and from ASCT are 35
months (range 5–192) and 18 months (range 1–54), respectively. At
the time of this analysis, no cases of either AML or sMDS have
developed. Fifty-seven patients died due to disease progression
with no signs of AML or sMDS. Furthermore, human androgen
receptor assay-polymerase chain reaction (HUMARA-PCR) analy-
sis of two patients with cytopenias did not show skewed X chromo-
some inactivation. Although median follow-up is short and the
number of cases at risk is small, thus far we have not observed any
cases of secondary AML or MDS in breast cancer patients receiv-
ing high-dose chemotherapy and autologous stem cell transplant.
EFFECT OF HIGH-DOSE CHEMOTHERAPY (HDC) AND AUTOLOGOUS
STEM CELL SUPPORT FOR BREAST CANCER ON CONCOMITANT
AUTOIMMUNE DISEASE
M.L. Keohan, D. Savage, K. Papadopolous, L. Vahdat, K. Antman, 
C.S. Hesdorffer
Herbert Irving Comprehensive Cancer Center, Columbia University,
New York, NY
HDC followed by autologous stem cell transplantation (ASCT) is
currently being evaluated as a means of delivering intense
immunomodulation for severe or poor prognosis autoimmune dis-
ease. We treated eight breast cancer patients with concomitant
autoimmune disease (lupus, Crohn’s, ulcerative colitis, multiple
sclerosis, sarcoid, mixed connective tissue disease, dermatomyositis,
psoriatic arthritis/psoriasis) with HD cyclophosphamide, thiotepa,
and carboplatin and unmanipulated ASCT. No patient experienced
a ﬂare of the underlying autoimmune disease at time of transplant
or during stem cell mobilization with chemotherapy and G-CSF.
Of the ﬁve patients on medications for active autoimmune disease
at transplant, one patient with Crohn’s required inpatient alimental
support 4 weeks after transplantation. A second patient with der-
matomyositis, which developed at relapse before HDC, was not
controlled despite tumor response. Clinical or serological manifes-
tations of autoimmune disease persisted or recurred shortly after
ASCT in the remaining three patients. The three patients with
quiescent disease remained without symptoms. Symptoms of
autoimmune disease did not correlate with later disease recurrence
in four patients. While four patients have continued control of
breast cancer, these patients’ concurrent autoimmune disease was
not appreciatively affected. Thus, transplant neither exacerbated
nor ameliorated the autoimmune disease.
AUTOLOGOUS BONE MARROW TRANSPLANTATION (ABMT) FOR
NON-HODGKIN’S LYMPHOMA (NHL) RESULTING IN LONG-TERM
REMISSION OF COINCIDENTAL CROHN’S DISEASE
A. Kashyap, S.J. Forman
City of Hope National Medical Center, Duarte, CA
Animal studies and reports of long-term remission after bone
marrow transplantation suggest that this procedure could be an
effective treatment for autoimmune diseases. Crohn’s disease is
thought to be an abnormal immune response to host antigens—a
form of autoimmune disease. This is the ﬁrst case report of long-
term remission of Crohn’s disease after ABMT. A 29-year-old
male was ﬁrst diagnosed in 1982 with Crohn’s disease. He received
intermittent treatment with prednisone and 6 MP for 6 years. In
1988, a peri-rectal abscess was treated by incision and drainage and
antibiotics. In 1989, a small bowel obstruction required extensive
surgery. In 1990, he developed generalized lymphadenopathy,
which was diagnosed as T-cell large-cell NHL (stage IVB). This
was treated with 1 cycle of CBV and 8 cycles of M-BACOD
chemotherapy and CNS chemo-prophylaxis resulting in ﬁrst CR.
Autologous peripheral blood stem cells were collected and cryopre-
served. In late 1990, Crohn’s disease recurred and NHL relapsed.
After one cycle of DHAP salvage chemotherapy, ABMT was per-
formed. Conditioning was with FTBI 200 cGy  6 doses, VP-16,
60 mg/kg; and cyclophosphamide 100 mg/kg. Unmanipulated stem
cells were reinfused and G-CSF was given posttransplant. His post-
transplant course was unremarkable. There has been no evidence
of recurrence of either NHL or Crohn’s disease in the 7 years fol-
lowing ABMT. Thus, this case report suggests that ABMT, as used
for the treatment of malignancy, may favorably influence the
course of Crohn’s disease.
ALLOGENEIC BMT/PBSCT PATIENTS WITH RELAPSED, REFRACTORY,
OR SECONDARY LEUKEMIA
M.G. Kiehl, I.W. Blau, N. Basara, D. Kirsten, A.A. Fauser
Department of Bone Marrow Transplantation, Idar-Oberstein, Germany
Hematological stem cell transplantation in patients with relapsed
or refractory leukemia is associated with a high mortality and
relapse rate and therefore still a matter of debate. Eighty-five
patients with refractory or relapsed (1 CR in ANLL, 2 CR in
ALL, 1 CP in CML) disease receiving HLA-matched (n29),
mismatched (n7) related donor or matched unrelated donor
(n53) between May 1994 and November 1997 at our institution
were analyzed. We treated 46 patients with ANLL, 21 with ALL,
16 with CML, and two with myelodysplasia (RAEB-T). Fifty-one
patients underwent MUD BMT or PBSCT (45 with bone marrow
stem cells, six with peripheral blood stem cells), 34 patients under-
went related donor BMT or PBSCT (20 with bone marrow stem
cells, 14 with peripheral blood stem cells). Medial age was 30 years
(17–58). Conditional regimen consisted of either FTBI (13.5 Gy)
and cyclophosphamide (120 mg/kg BW) or busulfan (16 mg/kg
BW) in combination with cyclophosphamide (120 mg/kg BW). All
patients transplanted from MUD or related donors received a short
course of MTX (day 1, 3, 5 in MUD and related mismatched trans-
plants), cyclosporine starting on day 3 and prednisolone starting
on day 7. Nineteen of 85 (21.3%) allogeneic transplanted patients
are still alive (median follow-up 300 days). The Kaplan-Meier esti-
mate of overall survival at 100 days for those patients is 53%. The
outcome of patients with relapsed or refractory ALL is 2/21 (9.5%).
The overall survival rate at 2 years is 13%. Relapse after transplan-
tation 38/70 (54%) was the major cause of death in these cohort
patients. Further improvement in the therapy of these highrisk
patients might be achieved by intensiﬁed cytostatic treatment before
transplantation, modulating graft-vs.-leukemia effects by biological
response modiﬁer (eg. interferon, interleukin), and by graft manipu-
lation (selective T-cell depletion, gene therapy, cytokines).
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SUBTOTAL LYMPHOID IRRADIATION FOR TREATMENT OF REFRACTORY
HEPATIC GRAFT-VS.-HOST DISEASE
A. Krishnan, H. Fung, A. Raubitschek, S.J. Forman
City of Hope National Medical Center, Duarte, CA
Subtotal lymphoid irradiation (STLI) has been used for treatment of
chronic graft-vs.-host disease (GVHD). Those regimens utilized low-
dose (1 Gy) single-fraction radiation. We modiﬁed this approach to
increase the immunosuppressive effects and used a ﬁvefold higher dose
delivered in divided fractions for a patient with refractory GVHD.
The patient developed grade II GVHD of the skin, liver, and gastroin-
testinal tract (GI) at day 33 following matched sibling transplant for
myelodysplasia. This was treated with prednisone (2mg/kg) with
improvement of GI symptoms and rash, but her bilirubin (BILI) rose to
7.7 mg/dL. Antithymocyte globulin (ATG) was given on day 43 at 20
mg/kg for 7 days with transient improvement. Because of progressive dis-
ease, a second course of ATG was administered. The GI symptoms and
skin rash improved; however, by day 104 the BILI rose to 16 mg/dL.
Liver biopsy conﬁrmed severe hepatic GVHD. Extracorporeal photo-
pheresis was performed, but her BILI continued to rise to 45 mg/dL.
STLI was started on day 118. Two areas were treated; a tight mantle ﬁeld
and a lower abdominal ﬁeld. Radiation was administered with 8 mV pho-
tons in 80 cGy fractions to both areas per day 2 times a week. A second
dose was given on day 127. The BILI dropped to 19 mg/dL by day 133.
Radiation fractions were later decreased to 50 cGy because of myelosup-
pression and possible GI toxicity, speciﬁcally three small episodes of lower
GI bleeding. She received a total of 510 cGy with a decrease and plateau
of her BILI at 8 mg/dL. She was then changed to FK506 and discharged
on day 204. Unfortunately she succumbed to pneumonia on day 245.
Low-dose STLI has reportedly caused improvement of skin and joint
manifestations in chronic GVHD. Our patient, in contrast, had acute to
chronic GVHD with primarily hepatic disease. The use of higher doses
of irradiation was feasible and led to signiﬁcant improvement in liver
function, allowing tapering of other immunosuppressive medications.
Her case suggests further exploration of STLI in drug refractory GVHD.
AUTOLOGOUS PERIPHERAL BLOOD PROGENITOR (PBPC) TRANS-
PLANTATION IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA
K.P. Papadopoulos, G. Nichols
Herbert Irving Cancer Center, New York, NY; 
Autologous PBPC transplantation for CML, utilizing chemotherapy mobi-
lized PBPCs, is an investigational procedure available to patients refusing or
without appropriate allogeneic donors. We present preliminary data on our
four patients (3 male, 1 female) with a median age of 48.5 (range 37–56) with
the longest follow-up, enrolled in our autologous PBPC protocol for CML.
All patients were treated with interferon (IFN) to maximal response. Dura-
tion of therapy was a median of 42 months (9–48 months). IFN was discon-
tinued for 4–6 weeks, and backup marrow was harvested and followed by
PBPC mobilization with chemotherapy. G-CSF was administered until com-
pletion of harvesting. Patients receiving ICE had nadir fever and required
blood product support. Ph quantitation was performed on the product.
Pre-BM Back-up Harvest
Pts Regimen Ph (%) Ph (%) Ph (%) Current
1 ICE 50 NA 20 50% 1.5y
2 ICE 100 100 100 100% 1.5y
3 IC 50 81 0 45% ly
4 IC 35 15 11 35% O.5y
ICE, idarubicin 6 mg/m2/Ara-C 600 mg/m2  5 days/etoposide 150 mg/m2
 3 days; IC, idarubicin 6 mg/m2/Ara-C 600 mg/m2  3 days.
Three of four patients had signiﬁcant decreases in percent Ph chromo-
somes. Our protocol delays the transplantation phase with BuCy condition-
ing until worsening response to IFN is demonstrated, or evidence of addi-
tional cytogenetic abnormalities. To date, none of these patients has
required the transplant portion of the protocol. While these are early results,
they demonstrate that: 1) despite IFN therapy for several years, adequate
PBPC can be harvested; 2) harvests containing decreased Ph stem cells can
be achieved safely after IC; 3) the use of G-CSF during mobilization does
not appear to alter kinetics of the Ph clone.
AUTOLOGOUS PERIPHERAL STEM CELL TRANSPLANTATION (PSCT) FOR
ADVANCED SOFT TISSUE SARCOMA
H. Myong, M. Lill, S. Pepkowitz, S. Hamburg, L. Qasabian, C. Hurvitz,
C. Forscher, F.J. Giles
Cedars-Sinai Medical Center, Los Angeles, CA
The 2-year survival of patients with advanced or recurrent soft tissue sar-
coma treated with standard chemotherapy (CTX) is 20% and long-term
remissions are rare. Between June 22, 1992 and January 31, 1997, we treated
11 patients with advanced soft tissue sarcoma. The mean age of the patients
at PSCT was 23 (8–42). There were seven histologic subtypes. Eight patients
had metastatic disease. Five patients had recurrent disease, four of whom had
metastatic disease. These 11 patients underwent a total of 16 PSCT. The
conditioning CTX for the PSCT were varied, but most commonly were
high-dose (HD) carboplatin (400–500 mg/m2  4 days) in ﬁve cases, and
HD ifosfamide (4–8 g  6–7 days) in seven cases.
Pre-PSCT treatments resulted in complete remission (CR) in four patients,
partial remission (PR) in four, and stable disease (SD) in three. There are
three disease-free (DF) survivors as of August 1997, one patient (8-year-old)
with recurrent hepatic sarcoma 4 years post-PSCT, one patient (21-year-old)
with metastatic Ewing’s sarcoma 21 months post-PSCT, and one patient (22-
year-old) with metastatic synovial sarcoma 11 months post-PSCT. The con-
ditioning regimen for the DF survivors included HD carboplatin in one, HD
ifosfamide in one, and etoposide/thiotepa/cytoxan in one. Two of the three
DF survivors were in CR before PSCT and the third DF survivor was in PR.
Two of three DF survivors had new onset metastatic sarcoma. One CR
patient is alive at 16 months post-PSCT with recurrent disease, and one PR
patient is alive at 7 months post-PSCT. Six remaining patients died of disease
with mean survival of 11 months post-PSCT (range 5–13 months). Three
patients with SD died of progressive disease at 5, 5.5, and 13 months post-
PSCT. There were no treatment-related deaths. Profound myelosuppression
was seen in all patients. One patient developed possible veno-occlusive disease
and died from progressive disease and one patient developed dialysis-depen-
dent renal failure but is alive and in remission 11 months post-PSCT.
High-dose CTX with PSCT can result in long-term DF survival for some
patients with advanced chemosensitive soft tissue sarcoma. Most of our
patients received multiple cycles of intermediate dose CTX before PSCT,
which resulted in high response rates. This therapy should be investigated in
patients with earlier stage disease at high risk of relapse or progression.
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HIGH-DOSE BCNU, ETOPOSIDE, AND THIOTEPA (BET) WITH AUTOL-
OGOUS HEMATOPOIETIC STEM CELL (PBPC) SUPPORT IN ADULTS
WITH BRAIN TUMORS (BT)
K.P. Papadopoulos, C. Balmaceda, M. Fetell, K.H. Antman, C.S. Hesdorffer
Herbert Irving Cancer Center, NY, NY
BCNU (B), etoposide (E), and thiotepa (T) are non–cross-resistant
agents with demonstrated activity against brain tumors. We conduct-
ed a phase I trial of high-dose B (450 mg/m2), E (1200 mg/m2) and
escalating dose T (500–800 mg/m2) in divided doses over 3 days with
autologous PBPC support in adults with brain tumors. Nineteen
patients (7 female, 12 male) of median age 42 (range 19–61) were
treated. Patients had newly diagnosed or recurrent GBM (11), recur-
rent anaplastic astrocytomas (2), recurrent anaplastic oligo-
dendrogliomas (5), and recurrent esthesioneuroblastoma (1). All
patients bar one had prior surgery and radiation therapy. Prior
chemotherapy included BCNU (1 cycle, range 1–8) in eight of 11
GBM patients. All oligodendrogliomas patients received PCV and
the esthesioblastoma patient received cyclophospharnide, cisplatin,
and etoposide. Cohorts were treated at level I (T  500 mg/m2, 4
patients), level II (T  600 mg/m2, 7 patients), level III (T 
700mg/m2, 4 patients) and level IV (T  800 mg/m2, 4 patients). Six-
teen patients had PBPCs re-infused, three had both PBPCs and BM.
All patients received G-CSF until hematopoietic recovery. Median
time to ANC 0.5109/L was 10 days (range 8–30) and platelets
20109/L was 11 days (range 9–65). Median hospital stay was 20
days (17–75), prbc use was 4 units (0–17), and platelet use was 3 units
(2–28). The toxic mortality rate was 5% (1 patient). Grade III–IV
reversible toxicities were mucositis (12), diarrhoea (7), vomiting (4),
fever (18), neurologic (4 [2 with seizures]) and elevated bilirubin (1).
The response rate was 13% in 15 evaluable patients: 2 CR, 11 SD,
and 2 PD. Median time to progression was 8 months and median OS
was 11 months. High-dose BET is a tolerable and safe regimen in
pretreated patients, and its efﬁcacy warrants further investigation in
patients with optimally resected chemoresponsive brain tumors.
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LYMPHOCYTE CHARACTERISTICS OF ALLOGENEIC BLOOD STEM
CELLS
Z. Steven Pavletic, Shantaram S. Joshi, Stefano R. Tarantolo, Anne
Kessinger, Michael R. Bishop
University of Nebraska Medical Center, Omaha, NE
Lymphocytes infused in mobilized allogeneic blood stem cell
(alloBSC) products may affect posttransplantation outcomes. Lym-
phocyte number and function were analyzed in alloBSC, G-
CSF–mobilized collections from 41 healthy HLA-identical sibling
donors. Absolute number of T-cell subsets and NK cells in allo-
BSC were 10–20 times higher than that in 6 allogeneic bone mar-
row (alloBM) harvests. On the functional level, interleukin-2
induced LAK cytotoxicity against K-562 and RAJI cell lines and
was significantly higher (p  0.001) in alloBSC than in normal
alloBM controls. Mobilization with G-CSF had no significant
impact on the composition of CD3, CD4, and CD8 subsets or on
the expression of adhesion molecules (CD80, CD49e, CD49d,
CD54) when compared with steady-state blood. However, there
was a signiﬁcant increase in number of CD56 cells after G-CSF
mobilization (p  0.05). Culturing alloBSC with IL-2 or IL-12
made no impact on composition of T-cell subsets or on adhesion
molecule expression if compared with pre-mobilization cultures.
G-CSF–mobilized donor cells exhibited significantly decreased
mitogen-induced T-cell proliferation (p  0.005), and decreased
lysis of tumor cell lines in NK and LAK assays (p  0.005). After
separation in CD3 or CD56 cell cultures, it was evident that the
post-mobilization decrease in NK or LAK cytotoxicity was con-
fined solely to CD3 cells, and there was no post-mobilization
change in cytotoxicity when CD56 effectors were used. Current
data suggest that certain quantitative and qualitative lymphocyte
characteristics in alloBSC products are modiﬁed by the mobiliza-
tion process. The clinical significance of these in vitro findings
remains to be determined.
AN UNUSUAL CASE OF ADULT RESPIRATORY DISTRESS SYNDROME
FOLLOWING GRANULOCYTE COLONY-STIMULATING FACTOR INJEC-
TIONS FOR STEM CELL MOBILIZATION FOR AUTOLOGOUS TRANS-
PLANTATION
Nabeel Rajeh, Nalini Janakiraman, Bennett Yu
Henry Ford Health System, Detroit, MI
A 37-year-old white man diagnosed in January 1996 with stage
IIIA diffuse large cell lymphoma received six cycles of ProMACE/
CytaBOM and achieved PR, which was followed by mediastinal
RT. He relapsed in December 1996 and was refractory to MINE
and DHAP chemotherapy, but achieved possible CR to CVPP 
5. High-dose chemotherapy with autologous stem cell transplanta-
tion was planned. He started G-CSF 10 g/kg/d SQ for stem cell
mobilization. On day 4 of G-CSF, he developed SOB that wors-
ened during the next 2 days. On day 6, his WBC was 39,900; he
was hypoxic; and his chest X-ray showed bilateral inﬁltrate. The
patient deteriorated rapidly, requiring intubation and mechanical
ventilation. Bronchoscopy and bronchoalveolar lavage were nondi-
agnostic. Bacteria, fungal, and viral cultures and PCP were nega-
tive. The patient was treated with prednisone (1 g/d  3 days) and
broad spectrum antibiotics. He had steady improvement and clear-
ing of inﬁltrate.
This case represents an unusual complication to G-CSF–induced
leukocytosis, which is similar to recently recognized retinoic acid
syndrome in settings of leukocytosis in patients with acute promye-
locytic leukemia treated with All trans-retinoic acid. With increas-
ing use of growth factors for mobilization of autologous stem cells,
this complication, though rare, should be in the differential diagno-
sis of diffuse pulmonary infiltrate. Allogeneic donors receiving
growth factors may also be at risk.
THE SCRIPPS CLINIC EXPERIENCE WITH TANDEM HIGH-DOSE
CHEMOTHERAPY (HDC) AND PERIPHERAL BLOOD PROGENITOR CELL
RESCUE (PBPCR) IN PATIENTS WITH METASTATIC BREAST CANCER (MBC)
N. Raja, W.E. Miller, R. McMillan, J.F. Kroener, T. Brehm, 
B.R. Meisenberg, J.R. Mason
Scripps Clinic, La Jolla, CA
The majority of patients with MBC have a poor prognosis with a
median survival of 2 years. We report the results of HDC with
PBPCR in 57 patients with MBC. Patient characteristics included a
median age of 46 years; 8 (14%) MBC at diagnosis, 16 (28%) locore-
gional and 33 (58%) distant relapse. Sites of disease in patients
included soft tissue/node (39 [68%]), bone (21 [36%]), lung/pleura (9
[15%]), liver (7 [12%]), and other (2 [3%]). The median number of
disease sites was l (1–3). Induction regimens, doxorubicin and/or tax-
ane-based had a median number of 4 (2–8). All patients had
chemosensitive disease sites. Thirty-three (59%) received tandem
HDC cycles: thiotepa 500 mg/m2, cyclophosphamide 6 g/m2, and
carboplatin 1.2 g/m2 or cisplatin 180 mg/m2 (cycle 1); melphalan 140
mg/m2 and carboplatin 1.2 g/m2 (cycle 2). Therapy was well tolerat-
ed, with grade III–IV nonhematologic toxicities primarily being nau-
sea (45%) and mucositis and diarrhea (29%), with no
treatment-related deaths. The median follow-up was 11 months.
Response data and Kaplan-Meier estimates of overall survival (OS)
and progression-free survival (PFS) at 42 months are shown below:
HDC cycles n CR % PR % NR % PD % PFS % OS %
Single 33 62 21 13 4 40 44
Tandem 24 67 18 3 3 31 55
Both 57 65 19 7 3 33 52
CR, complete response; PR, partial response; NR, no response; PD, progres-
sive disease. Response was unknown in three patients. 
We conclude that HDC is safe and well tolerated in patients with
MBC. Response rates are similar with single and tandem cycles; a
trend for improvement in OS is noted with tandem cycles of HDC.
PHASE 1/11 TRIAL OF MULTICYCLE PACLITAXEL/CARBOPLATIN/
TOPOTECAN/ETOPOSIDE/THIOTEPA WITH PERIPHERAL BLOOD
PROGENITOR (PBP) SUPPORT IN OVARIAN CANCER
V. Rella, W. Noguera, D. Smith, I. Wertheim, C. Hesdorffer, L. Vahdat,
T.J. Garrett, D. Savage, R.B. MacArthur, K. Antman, A. Tiersten
Herbert Irving Comprehensive Cancer Center, Columbia Presbyterian
Medical Center, New York, NY
Preclinical data suggest time and dose dependence for topotecan.
Topoisomerase I and II inhibitors may be synergistic when given
sequentially. We designed a phase I/II study of high-dose multi-
cycle chemotherapy (HDC) for patients with relapsed or persistent
ovarian cancer. Our objectives are to establish maximum tolerated
dose of topotecan combined with etoposide, to characterize phar-
macokinetics of 72-hour infusion of topotecan, to describe toxicities
and to evaluate response, time to progression, and disease-free and
overall survival. HDC consists of: cycle 1, paclitaxel (250 mg/m2)
with carboplatin (AUC 20); cycle 2, topotecan (starting dose 5
mg/m2 increasing by 2 mg/m2 increments) over 72 hours followed
in 48 hours by etoposide (600 mg/m2); cycle 3, thiotepa (500
mg/m2). PBP are reinfused 72 hours after chemotherapy. Seven
patients have been enrolled, with a total of 17 cycles administered
(four at dose level 1 and two at dose level 2 of topotecan). Three
patients entered HDC with disease 2 cm, four with 2 cm.
Non-hematologic toxicity (grade III–IV) included: cycle 1, grade III
diarrhea (3), grade III myalgia (2); cycle 2, grade II–IV pancreatitis
(1); cycle 3, none. There were nine post-treatment hospitalizations:
one for dehydration (secondary to nausea/vomiting/diarrhea), seven
for neutropenic fever requiring intravenous antibiotics (3 positive
blood cultures), one for non-neutropenic fever. Pretreatment
CA-125 levels were elevated and have normalized in all patients
who have completed therapy. Tandem cycles of HDC with PBP
support are feasible with insigniﬁcant nonhematologic toxicity at
dose levels 1 and 2. Readmission rates are acceptable. Enrollment
and pharmacokinetic analysis continues.
